NSE: ACI· ChemicalsNot in Aug top-30Small cap

Archean Chemical Industries

Bromine cost-curve leader

Last close
₹490.60
29 Sept 2026 · reference
1D · 1M
+1.6% · +1.3%
price-only
Weight
0.6%
31 Jul 2026 · Aug rank —
Thesis review
8 Sep 2026
Why We Own, p66
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • Q2FY27 results (Nov-2026): bromine volume run-rate progressing toward 20-24 kt and salt pricing stabilisation guided for H2FY27.
    C1
  • SOP phase-2 commissioning by Q3FY27 and continued Acume derivatives profitability.
    C2
  • SiCSem fab milestones (equipment orders with Aixtron, Clas-SiC integration) and any ISM disbursement news.
    C3
Material risks · 3
  • Bromine price volatility: prices already fell 11% QoQ in Jul-2026 as Chinese supply recovered; FY26 bromine revenue fell 13% and Q4FY26 had technical downtime.
    R1
  • Capital intensity and execution: borrowings up from Rs 98 cr (FY24) to Rs 466 cr (FY26) funding SOP, derivatives and the USD 250 mn SiC fab - a technology the company has no track record in; interest/depreciation already dragged Q1FY27 PAT -25%.
    R2
  • Salt business (66% of FY26 revenue) faces weak pricing and freight sensitivity; ROE only 5.4% in FY26 (3-yr 11%).
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01Bromine price volatility: prices already fell 11% QoQ in Jul-2026 as Chinese supply recovered; FY26 bromine revenue fell 13% and Q4FY26 had technical downtime.Research · post 2QFY27
02Capital intensity and execution: borrowings up from Rs 98 cr (FY24) to Rs 466 cr (FY26) funding SOP, derivatives and the USD 250 mn SiC fab - a technology the company has no track record in; interest/depreciation already dragged Q1FY27 PAT -25%.Research · post 2QFY27
03Salt business (66% of FY26 revenue) faces weak pricing and freight sensitivity; ROE only 5.4% in FY26 (3-yr 11%).Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01Q2FY27 results (Nov-2026): bromine volume run-rate progressing toward 20-24 kt and salt pricing stabilisation guided for H2FY27.
  • 02SOP phase-2 commissioning by Q3FY27 and continued Acume derivatives profitability.
  • 03SiCSem fab milestones (equipment orders with Aixtron, Clas-SiC integration) and any ISM disbursement news.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 491 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.